Manila Times Business
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs)Strengthened financial position with $27.5 million principal amount senior secured note financing and $50 million share purchase agreement to advance VERAXA’s pipeline of oncology drug candidates utilizing its novel BiTAC platformVERAXA rece
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Debut Novel by Susan Price Brings 1970s Newport to Life in Summer Read
2h ago
West Red Lake Gold Announces Results of Annual General Meeting
2h ago
Fennec Announces Results of Annual Meeting
2h ago
Credit Acceptance Announces Appointment of Joe Billante as Chief Financial Officer; Jay Martin to Retire After More Than Two Decades of Service
2h ago